Earth Science Tech, Inc. Signs Agreement with TransBiotech to start in Vitro & in Vivo in Phase II for Nutraceutical Patents
November 14, 2017 08:00 ET
|
Earth Science Tech, Inc.
Doral, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company that operates in the fields of industrial hemp...
Devonian annonce l’initiation de l’étude clinique de Phase IIa du Thykamine(MC) chez les patients atteints de Dermatite Atopique légère à modérée
November 09, 2017 08:45 ET
|
Groupe Santé Devonian Inc.
NE PAS DISTRIBUER AUX AGENCES DE PRESSE AMÉRICAINES NI DIFFUSER AUX ÉTATS-UNIS QUÉBEC, 09 nov. 2017 (GLOBE NEWSWIRE) -- Groupe Santé Devonian Inc. (« Devonian » ou la « Société ») (TSX...
Devonian Announces Initiation of Phase IIa Clinical Trial of Thykamine™ in Adult patients with Mild-to-Moderate Atopic Dermatitis
November 09, 2017 08:45 ET
|
Devonian Health Group Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES QUEBEC CITY, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Devonian Health Group Inc. ("Devonian" or the "Corporation")...
WOWIO, INC. Acquires Land to be developed into low cost housing in Northern California
November 09, 2017 06:30 ET
|
Wowio, Inc.
WOWIO Continues to Build its base of new Businesses Henderson, NV, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Wowio, Inc. (OTC Pink: WWIO) “WWIO or The Company” has entered into an agreement for its wholly...
Summit Highlights Microbiome Preservation During Ridinilazole Treatment in Exploratory Phase 2 Clinical Trial at ID Week 2017
October 09, 2017 07:00 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Oct. 09, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
ContraFect Announces Second Quarter 2017 Financial Results
August 09, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - August 09, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
Earth Science Tech Inc. Signs Contract with CDBQ to Advance Phase-2 Rollout on it’s CBD Patents
August 01, 2017 08:25 ET
|
Earth Science Tech, Inc.
Hollywood, FL, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotechnology company that operates in the fields of hemp...
Esperion Announces Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor
July 26, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., July 26, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Neuralstem Reports Last Subject Out in Phase 2 Trial of NSI-189 for Major Depressive Disorder
May 17, 2017 16:05 ET
|
Neuralstem, Inc.
GERMANTOWN, Md., May 17, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing next generation treatments for nervous system diseases, today announced it has...
Akari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and in Additional Clinical Targets
April 24, 2017 07:15 ET
|
Akari Therapeutics, Plc
-Interim Phase 2 PNH data demonstrate positive response with Coversin™-Phase 3 PNH program expected to commence in 4Q2017-Data from preclinical aHUS model demonstrates positive results-New preclinical...